Based on the Tilray Inc stock forecast from 4 analysts, the average analyst target price for Tilray Inc is USD 2.04 over the next 12 months. Tilray Inc’s average analyst rating is Hold . Stock Target Advisor’s own stock analysis of Tilray Inc is Slightly Bearish, which is based on 3 positive signals and 6 negative signals. At the last closing, Tilray Inc’s stock price was USD 1.38. Tilray Inc’s stock price has changed by -10.97% over the past week, -13.21% over the past month and -20.23% over the last year.
No recent analyst target price found for Tilray Inc
No recent average analyst rating found for Tilray Inc
Company Overview Tilray Inc
Tilray Brands, Inc., a lifestyle consumer products company, engages in the research, cultivation, processing, and distribution of medical cannabis products in Canada, the United States, Europe, Australia, New Zealand, Latin America, and internationally. The company operates through four segments: Beverage Alcohol, Cannabis, Distribution, and Wellness. It also offers medical and adult-use cannabis products; purchases and resells pharmaceutical and wellness products; and produces, markets, sells, and distributes beverage alcohol products, and hemp-based food and other wellness products. The company offers its products under the Tilray, Aphria, Broken Coast, Symbios, Navcora, Charlotte's Web, Montauk Brewing, Shock Top, 10 Barrell, Breckenridge Brewery, SweetWater Brewing, Breckenridge Distillery, Blue Point Brewing, Broken Coast, Redecan, XMG, Manitoba Harvest, CC Pharma, Good Supply, Solei, Mollo, Chowie Wowie, Original Stash, Canaca, RIFF, Bake Sale, The Batch, HEXO, Alpine Beer Company, Green Flash, Hiball Energy, Redhook Brewery, Square Mile Cider, Widmer Brothers Brewing, Runner's High Brewing Company, Happy Flower, and Fresh Hemp Foods brands. It sells its products to retailers, wholesalers, patients, physicians, hospitals, pharmacies, researchers, and governments, as well as direct to consumers. The company was formerly known as Tilray, Inc. and changed its name to Tilray Brands, Inc. in January 2022. Tilray Brands, Inc. is headquartered in Leamington, Canada. Read Less
Tilray Brands, Inc., a lifestyle consumer products company, engages in the research, cultivation, processing, and distribution of medical cannabis products in Canada, the United States, Europe, Australia, New Zealand, Latin America, and internationally. The company operates throu...Read More
Frequently Asked Questions About Tilray Inc (TLRY) Stock
Based on ratings from 4 analysts Tilray Inc's stock is Hold . Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 1 buy, sell and 5 hold ratings.
Unfortunately we do not have enough data on TLRY's stock to indicate if its a good dividend stock.
Based on targets from 4 analysts, the average taret price for TLRY is USD 2.04 over the next 12 months. The maximum analyst target price is USD 2.5 while the minimum anlayst target price is USD 1.75.
TLRY stock's Price/Earning ratio is 7.34.
Our analysis grades TLRY stock's Price / Earning ratio at C. This means that TLRY stock's Price/Earning ratio is above 26% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NSD exchange.
Based on this TLRY may be undervalued for its sector.
The last closing price of TLRY's stock was USD 1.38.
The most recent market capitalization for TLRY is USD 1.35B.
Based on targets from 4 analysts, the average taret price for TLRY is projected at USD 2.04 over the next 12 months.
This means that TLRY's stock price may go up by +47.95% over the next 12 months.
We can't find any ETFs which contains Tilray Inc's stock.
As per our most recent records Tilray Inc has 2,650 Employees.
Tilray Inc's registered address is 265 Talbot Street West, Leamington, ON, Canada, N8H 5L4.
You can get more information about it from Tilray Inc's website at https://www.tilray.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
What not to like
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About Tilray Inc (TLRY) Stock
Based on ratings from 4 analysts Tilray Inc's stock is Hold . Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 1 buy, sell and 5 hold ratings.
Unfortunately we do not have enough data on TLRY's stock to indicate if its a good dividend stock.
Based on targets from 4 analysts, the average taret price for TLRY is USD 2.04 over the next 12 months. The maximum analyst target price is USD 2.5 while the minimum anlayst target price is USD 1.75.
TLRY stock's Price/Earning ratio is 7.34.
Our analysis grades TLRY stock's Price / Earning ratio at C. This means that TLRY stock's Price/Earning ratio is above 26% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NSD exchange.
Based on this TLRY may be undervalued for its sector.
The last closing price of TLRY's stock was USD 1.38.
The most recent market capitalization for TLRY is USD 1.35B.
Based on targets from 4 analysts, the average taret price for TLRY is projected at USD 2.04 over the next 12 months.
This means that TLRY's stock price may go up by +47.95% over the next 12 months.
We can't find any ETFs which contains Tilray Inc's stock.
As per our most recent records Tilray Inc has 2,650 Employees.
Tilray Inc's registered address is 265 Talbot Street West, Leamington, ON, Canada, N8H 5L4.
You can get more information about it from Tilray Inc's website at https://www.tilray.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for TLRY !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
